Health Risk Factor Week
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Antisense Pharma GmbH
Antagonists to melanoma-inhibiting activity foil immunosuppression
March 22nd, 2005
Antagonists to melanoma-inhibiting activity foil immunosuppression. "Melanoma inhibitory activity (MIA) is an 11 kD protein secreted by malignant melanomas. Recent studies revealed an interaction of MIA with epitopes of extracellular matrix proteins including fibronectin. Structural homology of MIA with the binding sites of alpha4beta1 integrin results in complex interactions of MIA with molecules binding to alpha4beta1 integrin," scientists in Germany report. "As cells of the immune system express alpha4beta1 integrins (VLA-4), we investigated whether MIA may modulate the function of human leukocytes. Here we describe the effects of MIA on the...
Source: Health Risk Factor Week (2005-03-22)
|
